Biothera and Massachusetts Institute of Technology (MIT) filed a patent infringement lawsuit today against Biorgin, a Brazilian company, for selling beta 1,3/1,6 gluco polysaccharide ingredients in the U.S. for nutritional supplements and functional foods. Biothera and MIT charged Biorigin with six counts of patent infringement in a lawsuit filed in U.S. District Court, Northern District of Illinois. Massachusetts Institute of Technology owns and licenses to Biothera certain patents that are part of the litigation. The plaintiffs seek a permanent injunction and unspecified damages from Biorigin. “Biothera has a formidable intellectual property portfolio that provides exclusivity to market our gluco polysaccharide in the U.S.,” said Richard G. Mueller, Biothera president and chief executive officer. Biothera has more than 40 U.S. patents and patents pending, as well as additional patents in more than 20 countries, protecting the matter of composition, manufacturing and use of beta 1,3/1,6 gluco polysaccharide derived from yeast (Saccharomyces cerevisiae).

Posted by GEN-ERIC at 12:00:56 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/1253

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)